PURE Bioscience Q3 net loss widens; announces CEO transition

Pure Biosciences

15/06/2026 21:22

Overview
US antimicrobial products developer's fiscal Q3 revenue rose slightly year-over-year
Company's net loss widened in fiscal Q3, while net loss per share was unchanged
CEO to retire at fiscal year-end; Co's president, Jeff Kitchell, appointed as successor effective August 1, 2026

Outlook
Company did not provide specific financial guidance for the current or upcoming periods

Result Drivers
DISTRIBUTION NETWORK - Co attributed slight Q3 revenue growth to higher sales across its distribution network
NEW PRODUCT ADOPTION - Initial sales of PURE Clean and expansion into new industries, including dairy, contributed to growth, per President Jeff Kitchell
TRANSPORTATION SECTOR GROWTH - Increased adoption of trailer treatment programs and launch of PURE Fleet Wash drove growth in transportation segment

Company press release: ID:nBwbYHw9ba

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q3 EPS
 
-$0.01

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)